New Products

Lentiviral SARS-CoV-2 Pseudovirus

To understand the mechanism of SARS-CoV-2 cell entry, it is essential to study how Spike proteins interact with the ACE2 receptor. However, such studies are hampered by the danger of producing and manipulating live coronavirus. Live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Pseudoviruses are useful virological tools because of their safety and versatility, the pseudovirus is restricted to a single round of replication and can be handled using BSL-2 containment practices.

Product Description

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike display antigenically correct spike protein pseudotyped (Wuhan-Hu-1 strain or D614G mutant) on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core and are capable of a single round of infection and carry a genome that expresses either a GFP or luciferase optical reporter gene upon infection.

Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene and can be used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV- 2 spike protein.

Lentiviral SARS-CoV-2 Pseudovirus

Pseudotyped Luciferase/GFP VSV is designed as a control for CD’s Pseudotyped Luciferase/GFP rSARS-CoV-2 Spike to test for non-specific factors that affect virus infectivity. The Pseudovirus display the VSV envelope glycoprotein (VSV-G) pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. The VSV-G protein confers the Pseudovirus with a high level of single cycle infectivity due to its broad tropism.

The Pseudotyped Luciferase/GFP Lentivirus was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the Luciferase gene or GFP driven by a CMV promoter as the reporter. Since the virus is lacking the envelope glycoproteins and cannot be transfected to target cells. The Pseudotyped Luciferase Lentivirus can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors.

Typical Data

Typical Data for Lentiviral SARS-CoV-2 Pseudovirus

HEK-293T cells stably expressing ACE2 or HEK293T cells were incubated with lentivirus pseudotyped with the SARS-CoV-2 spike glycoprotein (CD Cat# COV-PS02) for 12 h.

Bayati A, Kumar R, Francis V, et al. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis[J]. Journal of Biological Chemistry, 2021, 296: 100306.

Neutralization Assay By Serum

Typical Data for Lentiviral SARS-CoV-2 Pseudovirus

WT and Control Product List

Cat# Product Name Reporter Gene Envelope Glycoproteins
COV-PS01 Pseudotyped Luciferase rSARS-CoV-2 Spike Luciferase SARS-CoV-2 Spike (Wuhan-Hu-1)
COV-PS02 Pseudotyped GFP rSARS-CoV-2 Spike GFP SARS-CoV-2 Spike (Wuhan-Hu-1)
COV-PS12 Pseudotyped GFP-Luc rSARS-CoV-2 Spike, WT GFP/Luciferase Dual Reporter SARS-CoV-2 Spike (Wuhan-Hu-1)
COV-PS03 Pseudotyped rSARS-CoV-2 Spike × SARS-CoV-2 Spike (Wuhan-Hu-1)
COV-PSL1 Pseudotyped Luciferase Lentivirus Luciferase ×
COV-PSG2 Pseudotyped GFP Lentivirus GFP ×

Our team has been working diligently to stay abreast these new developments and are currently developing a serial of Lentiviral SARS-CoV-2 Mutation Pseudovirus, including Delta, Lambda, Zeta, Alpha, Gamma, Beta, Kappa.

Variants of Concern Product List

Cat# Product Name Reporter Gene Envelope Glycoproteins
COVL-DE2 Pseudotyped Luciferase rSARS-CoV-2 Spike, Indian variant B.1.617.2 (Delta) Luciferase SARS-CoV-2 Spike (Indian variant B.1.617.2; T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N)
COVG-DE2 Pseudotyped GFP rSARS-CoV-2 Spike, Indian variant B.1.617.2 (Delta) GFP SARS-CoV-2 Spike (Indian variant B.1.617.2; T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N)
COVL-B1617 Pseudotyped Luciferase rSARS-CoV-2 Spike (Indian variant B.1.617, RBD mutations only) Luciferase SARS-CoV-2 Spike (Indian variant B.1.617, RBD mutations only; L452R, E484Q, D614G)
COVG-B1617 Pseudotyped GFP rSARS-CoV-2 Spike (Indian variant B.1.617, RBD mutations only) GFP SARS-CoV-2 Spike (Indian variant B.1.617, RBD mutations only; L452R, E484Q, D614G)
COVL-KA1 Pseudotyped Luciferase rSARS-CoV-2 Spike, Indian variant B.1.617.1 (Kappa) Luciferase SARS-CoV-2 Spike (Indian variant B.1.617.1; G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H)
COVG-KA1 Pseudotyped GFP rSARS-CoV-2 Spike, Indian variant B.1.617.1 (Kappa) GFP SARS-CoV-2 Spike (Indian variant B.1.617.1; G142D, E154K, L452R, E484Q, D614G, P681R, Q1071H)
COVL-DE417 Pseudotyped Luciferase rSARS-CoV-2 Spike, B.1.617.2.1 Variant (Delta + K417N) Luciferase SARS-CoV-2 Spike (DELTA PLUS (Delta + K417N) B.1.617.2.1; T19R, G142D, del156-157, R158G, K417N, L452R, T478K, D614G, P681R, D950N)
COVG-DE417 Pseudotyped GFP rSARS-CoV-2 Spike, B.1.617.2.1 Variant (Delta + K417N) GFP SARS-CoV-2 Spike (DELTA PLUS (Delta + K417N) B.1.617.2.1; T19R, G142D, del156-157, R158G, K417N, L452R, T478K, D614G, P681R, D950N)
COVL-LA37 Pseudotyped Luciferase rSARS-CoV-2 Spike, C.37 Variant (Lambda) Luciferase SARS-CoV-2 Spike (Variant C.37; G75V, T76I, R246N, del247-253, L452Q, F490S, D614G, T859N)
COVG-LA37 Pseudotyped GFP rSARS-CoV-2 Spike, C.37 Variant (Lambda) GFP SARS-CoV-2 Spike (Variant C.37; G75V, T76I, R246N, del247-253, L452Q, F490S, D614G, T859N)
COVL-ZE2 Pseudotyped Luciferase rSARS-CoV-2 Spike, Brazilian variant P.2 (Zeta) Luciferase SARS-CoV-2 Spike (Brazilian variant P.2; E484K, V1176F, D614G)
COVG-ZE2 Pseudotyped GFP rSARS-CoV-2 Spike, Brazilian variant P.2 (Zeta) GFP SARS-CoV-2 Spike (Brazilian variant P.2; E484K, V1176F, D614G)
COVL-B117 Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant B.1.1.7, Alpha) Luciferase SARS-CoV-2 Spike (Variant B.1.1.7; deletion H69-V70, deletion Y144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H)
COVG-B117 Pseudotyped GFP rSARS-CoV-2 Spike (Variant B.1.1.7, Alpha) GFP SARS-CoV-2 Spike (Variant B.1.1.7; deletion H69-V70, deletion Y144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H)
COVL-BE1 Pseudotyped Luciferase rSARS-CoV-2 Spike (Variant South African variant Δ3 B.1.351, 20H/501Y.V2, Beta) Luciferase SARS-CoV-2 Spike (South African variant Δ3 B.1.351, 20H/501Y.V2, Beta; L18F, D80A, D215G, ΔL242/A243/L244, R246I, K417N, N501Y, E484K, D614G, A701V)
COVG-BE1 Pseudotyped GFP rSARS-CoV-2 Spike (Variant South African variant Δ3 B.1.351, 20H/501Y.V2, Beta) GFP SARS-CoV-2 Spike (South African variant Δ3 B.1.351, 20H/501Y.V2, Beta; L18F, D80A, D215G, ΔL242/A243/L244, R246I, K417N, N501Y, E484K, D614G, A701V)
COVL-501YV2 Pseudotyped Luciferase rSARS-CoV-2 Spike (South African variant B.1.351, 20C/501Y.V2) Luciferase SARS-CoV-2 Spike (South African variant B.1.351, 20C/501Y.V2; L18F, D80A, D215G, L242H, R246I, K417N, N501Y, E484K, D614G, A701V)
COVG-501YV2 Pseudotyped GFP rSARS-CoV-2 Spike (South African variant B.1.351, 20C/501Y.V2) GFP SARS-CoV-2 Spike (South African variant B.1.351, 20C/501Y.V2; L18F, D80A, D215G, L242H, R246I, K417N, N501Y, E484K, D614G, A701V)
COVL-JBV1 Pseudotyped Luciferase rSARS-CoV-2 Spike, Japanese/Brazilian Variant (P.1, Gamma) Luciferase SARS-CoV-2 Spike (Variant Japanese/Brazilian Variant (P.1); L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F)
COVG-JBV1 Pseudotyped GFP rSARS-CoV-2 Spike, Japanese/Brazilian Variant (P.1, Gamma) GFP SARS-CoV-2 Spike (Variant Japanese/Brazilian Variant (P.1); L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F)
COVL-B11318 Pseudotyped Luciferase rSARS-CoV-2 Spike, B.1.1.318 UK Luciferase SARS-CoV-2 Spike (T95I, ΔY144, E484K, D614G, P681H, D796H)
COVG-B11318 Pseudotyped GFP rSARS-CoV-2 Spike, B.1.1.318 UK GFP SARS-CoV-2 Spike (T95I, ΔY144, E484K, D614G, P681H, D796H)
COVL-D641G Pseudotyped Luciferase rSARS-CoV-2 Spike D614G Luciferase SARS-CoV-2 Spike (D614G)
COVG-D641G Pseudotyped GFP rSARS-CoV-2 Spike D614G GFP SARS-CoV-2 Spike (D614G)
COVL-E484K Pseudotyped Luciferase rSARS-CoV-2 Spike, E484K Luciferase SARS-CoV-2 Spike (E484K)
COVG-E484K Pseudotyped GFP rSARS-CoV-2 Spike, E484K GFP SARS-CoV-2 Spike (E484K)
COVL-N439K Pseudotyped Luciferase rSARS-CoV-2 Spike (N439K) Luciferase SARS-CoV-2 Spike (N439K)
COVG-N439K Pseudotyped GFP rSARS-CoV-2 Spike (N439K) GFP SARS-CoV-2 Spike (N439K)
COVL-N439KB Pseudotyped Luciferase rSARS-CoV-2 Spike, N439K/D614G Luciferase SARS-CoV-2 Spike (N439K, D614G)
COVG-N439KB Pseudotyped GFP rSARS-CoV-2 Spike, N439K/D614G GFP SARS-CoV-2 Spike (N439K, D614G)
COVL-DC5 Pseudotyped Luciferase rSARS-CoV-2 Spike, Danish/mink Cluster 5 (dFVI) Luciferase SARS-CoV-2 Spike (ΔH69/V70, Y453F, I692V, M1229I)
COVG-DC5 Pseudotyped GFP rSARS-CoV-2 Spike, Danish/mink Cluster 5 (dFVI) GFP SARS-CoV-2 Spike (ΔH69/V70, Y453F, I692V, M1229I)
COVL-N501Y Pseudotyped Luciferase rSARS-CoV-2 Spike, N501Y (US/Ohio Strain, COHD32 or COH.20g/501Y) Luciferase SARS-CoV-2 Spike (N501Y, D614G)
COVG-N501Y Pseudotyped GFP rSARS-CoV-2 Spike, N501Y (US/Ohio Strain, COHD32 or COH.20g/501Y) GFP SARS-CoV-2 Spike (N501Y, D614G)
COVL-S477N Pseudotyped Luciferase rSARS-CoV-2 Spike, S477N (Australian mutation, Hodcroft 2020) Luciferase SARS-CoV-2 Spike (S477N, D614G)
COVG-S477N Pseudotyped GFP rSARS-CoV-2 Spike, S477N (Australian mutation, Hodcroft 2020) GFP SARS-CoV-2 Spike (S477N, D614G)

Custom Lentiviral SARS-CoV-2 Pseudovirus

CD offers a variety of lentiviral SARS-CoV-2 pseudovirus from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means. If you can't a find a suitable pseudovirus above, please contact us for custom options.

Catalog No. Product Description Envelope Glycoproteins Lead Time
PSV-Custom SARS-CoV-2 Spike protein-pseudotyped lentiviral particles, GFP/Luciferase reporter gene Custom mutations 6 weeks

Click here to view our Pseudotyped VSV-SARS-CoV-2 Spike

Related Products

Inquiry Basket